Diagnostics

Artificial Intelligence Imaging Solutions Blood Testing Molecular Testing Blood Analysis Cancer Testing Patient Monitoring Point-of-Care Testing Software Solutions Cancer Detection Healthcare Infrastructure Blood Tests Imaging Devices Cancer Care Biosciences

3 ARTICLES

last mo.

FDA Clears Tempus xT CDx to Run as Tumor‑Only Diagnostic

The approval removes the matched‑normal requirement so clinicians can test tumor tissue alone and opens a path for Tempus to migrate its DNA solid‑tumor tests into FDA‑cleared assays under ADLT pricing.

6 ARTICLES

2mo ago

Roche to Acquire PathAI for $750 Million Upfront Plus Up to $300 Million in Milestones

11 ARTICLES

6mo ago

Minot Light’s Q3 Letter Posts 7.6% Gain, Trails Micro‑Cap Benchmark, Highlights Arq, Lucid and Stran

5 ARTICLES

this yr.

Waters to Acquire BD’s Biosciences and Diagnostics Business Through $17.5 Billion Reverse Morris Trust